BHC Stock Forecast & Price Target

Bausch Health Companies Inc. demonstrated solid performance in its revenue segments, with Diversified Products reporting steady growth and outperforming expectations by approximately 3% against RBC estimates and 4% against consensus. Additionally, the strong growth observed in Canada, specifically a 20% year-over-year organic increase driven by Ryaltris and promoted products, highlights the company's effective market strategies. Furthermore, Solta Medical achieved remarkable revenue growth of 28% year-over-year, exceeding both RBC estimates and consensus expectations, which underscores the potential for the company’s ongoing expansion and financial health.

Bausch Health Companies reported a year-over-year decline of 1% in international revenues, which was below consensus expectations, highlighting potential challenges in sustaining top-line growth. The Latin America region demonstrated a significant revenue decrease of 14% year-over-year, suggesting regional weaknesses that could further impact the company's overall performance. Additionally, projected modeling indicates a concerning 7% year-over-year revenue decline in 2027 due to anticipated IRA-related headwinds, emphasizing underlying vulnerabilities in financial outlook.